Nimesulide tablets—Approved for Marketing
On April 21, 2026, our company's nimusulide tablets were approved for market launch. The product was approved under the new chemical drug registration category, which is equivalent to passing the consistency evaluation. This medication is classified as a Category A drug under the national medical insurance system.
Nimesulide is a novel nonsteroidal anti-inflammatory drug (NSAID) that primarily functions by selectively inhibiting the COX-2 enzyme, offering three therapeutic effects: fever reduction, pain relief, and anti-inflammatory action. It is commonly used in clinical practice to alleviate pain and discomfort caused by various conditions such as arthritis, rheumatoid osteoarthritis, and muscular pain.
